Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (15)
  • Open Access

    REVIEW

    Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review

    Jiahao Su*, Meiqin Cai*, Wensheng Li*, Bo Hou, Haiyong He, Cong Ling,Tengchao Huang, Huijiao Liu, Ying Guo*

    Oncology Research, Vol.24, No.2, pp. 117-128, 2016, DOI:10.3727/096504016X14612603423511

    Abstract Glioblastoma (GBM) is the most common primary malignant brain tumor that nearly always results in a bad prognosis. Temozolomide plus radiotherapy (TEM+RAD) is the most common treatment for newly diagnosed GBM. With the development of molecularly targeted drugs, several clinical trials were reported; however, the efficacy of the treatment remains controversial. So we attempted to measure the dose of the molecularly targeted drug that could improve the prognosis of those patients. The appropriate electronic databases (PubMed, MEDLINE, EMBASE, and the Cochrane Library) were searched for relevant studies. A meta-analysis was performed after determining which studies… More >

  • Open Access

    ARTICLE

    Phase II Trial of Intensity-Modulated Radiotherapy Concurrent With Chemotherapy for Postoperative Node-Positive Esophageal Squamous Cell Carcinoma

    Hua Tao, Yiqin Zhou, Chengyun Yao, Dayong Gu, Wei Chen, Jincheng Lu

    Oncology Research, Vol.25, No.8, pp. 1357-1362, 2017, DOI:10.3727/096504017X14889842609577

    Abstract The aim of this study was to evaluate the efficacy and toxicity of intensity-modulated radiotherapy concurrent with weekly docetaxel in patients with node-positive esophageal squamous cell carcinoma after radical surgery. Between January 2011 and December 2013, a total of 46 eligible patients were enrolled. All patients received intensity-modulated radiotherapy concurrent with weekly docetaxel (20 mg/m2 ). Patients were treated 5 days per week at 2.0 Gy/day. The total dose of external radiotherapy given was 50 Gy in 25 fractions. The primary endpoints included treatment completion and safety. The secondary endpoint was to assess whether the approach… More >

  • Open Access

    ARTICLE

    Long Noncoding RNA CRNDE/PRC2 Participated in the Radiotherapy Resistance of Human Lung Adenocarcinoma Through Targeting p21 Expression

    Ming Zhang*, Change Gao, Yi Yang*, Gaofeng Li, Jian Dong§, Yiqin Ai*, Nan Chen, Wenhui Li*

    Oncology Research, Vol.26, No.8, pp. 1245-1255, 2018, DOI:10.3727/096504017X14944585873668

    Abstract Long noncoding RNAs (lncRNAs), a new class of functional regulators involved in human tumorigenesis, have been attracting the increasing attention of researchers. The lncRNA colorectal neoplasia differentially expressed (CRNDE) gene, transcribed from chromosome 16 on the strand opposite the adjacent IRX5 gene, was originally found to be increased in CRC and was reported to be abnormally expressed in many cancers. However, its potential role and the molecular mechanism underlying the radioresistant phenotype formation of lung adenocarcinoma (LAD) remain unclear. In our present study, we identified that CRNDE was significantly upregulated in LAD tissue and radioresistant… More >

  • Open Access

    ARTICLE

    Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution

    Wang Fangzheng*†1, Jiang Chuner‡1, Ye Zhiming*†, Liu Tongxin*†, Yan Fengqin*†, Wang Lei*†, Li Bin*†, Hu Fujun*†, Chen Ming*†, Qin Weifeng*†, Fu Zhenfu*†

    Oncology Research, Vol.26, No.2, pp. 277-287, 2018, DOI:10.3727/096504017X15079846743590

    Abstract In this retrospective review of a single institution’s experience, the efficacy and safety of the long-term use of nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC) were studied. Between August 2008 and March 2014, 39 newly diagnosed patients with stages III–IV NPC were treated with IMRT, chemotherapy, and nimotuzumab. Twenty patients were diagnosed with stage III (51.3%), 14 with stage IVA (35.9%), and 5 with stage IVB (12.8%) disease. All patients received at least one cycle of cisplatin-based induction chemotherapy followed by IMRT and more… More >

  • Open Access

    ARTICLE

    Predicting 3D Radiotherapy Dose-Volume Based on Deep Learning

    Do Nang Toan1,*, Lam Thanh Hien2, Ha Manh Toan1, Nguyen Trong Vinh2, Pham Trung Hieu1

    Intelligent Automation & Soft Computing, Vol.39, No.2, pp. 319-335, 2024, DOI:10.32604/iasc.2024.046925

    Abstract Cancer is one of the most dangerous diseases with high mortality. One of the principal treatments is radiotherapy by using radiation beams to destroy cancer cells and this workflow requires a lot of experience and skill from doctors and technicians. In our study, we focused on the 3D dose prediction problem in radiotherapy by applying the deep-learning approach to computed tomography (CT) images of cancer patients. Medical image data has more complex characteristics than normal image data, and this research aims to explore the effectiveness of data preprocessing and augmentation in the context of the… More >

  • Open Access

    ARTICLE

    A Novel Unsupervised MRI Synthetic CT Image Generation Framework with Registration Network

    Liwei Deng1, Henan Sun1, Jing Wang2, Sijuan Huang3, Xin Yang3,*

    CMC-Computers, Materials & Continua, Vol.77, No.2, pp. 2271-2287, 2023, DOI:10.32604/cmc.2023.039062

    Abstract In recent years, radiotherapy based only on Magnetic Resonance (MR) images has become a hot spot for radiotherapy planning research in the current medical field. However, functional computed tomography (CT) is still needed for dose calculation in the clinic. Recent deep-learning approaches to synthesized CT images from MR images have raised much research interest, making radiotherapy based only on MR images possible. In this paper, we proposed a novel unsupervised image synthesis framework with registration networks. This paper aims to enforce the constraints between the reconstructed image and the input image by registering the reconstructed… More >

  • Open Access

    ARTICLE

    Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells

    ROGHAYEH GHORBANI1, MAHMOUD GHARBAVI2, ALI SHARAFI3,4, ELHAM RISMANI5, HAMED REZAEEJAM6, YOUSEF MORTAZAVI1,*, BEHROOZ JOHARI3,*

    Oncology Research, Vol.32, No.1, pp. 101-125, 2024, DOI:10.32604/or.2023.044741

    Abstract In the present study, we investigated the synergistic effects of targeted methotrexate-selenium nanostructure containing Myc decoy oligodeoxynucleotides along with X-irradiation exposure as a combination therapy on LNCaP prostate cancer cells. Myc decoy ODNs were designed based on the promoter of Bcl-2 gene and analyzed by molecular docking and molecular dynamics assays. ODNs were loaded on the synthesized Se@BSA@Chi-MTX nanostructure. The physicochemical characteristics of nanostructures were determined by FTIR, DLS, UV-vis, TEM, EDX, in vitro release, and hemolysis tests. Subsequently, the cytotoxicity properties of them with and without X-irradiation were investigated by uptake, MTT, cell cycle, apoptosis, and… More > Graphic Abstract

    Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells

  • Open Access

    ARTICLE

    Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study

    SUKRAN SENYUREK1, SEZER SAGLAM2,*, ESRA KAYTAN SAGLAM3, HAKAN YANAR4, KAAN GOK4, DIDEM TASTEKIN5, CANAN KOKSAL AKBAS6, NERGIZ DAGOGLU SAKIN3, GULBIZ DAGOGLU KARTAL7, EMRE BALIK8, METIN KESKIN4, YASEMIN SANLI9, MINE GULLUOGLU10, ZULEYHA AKGUN11

    Oncology Research, Vol.31, No.5, pp. 689-696, 2023, DOI:10.32604/or.2023.030351

    Abstract Radiation therapy (RT) is typically applied using one of two standard approaches for preoperative treatment of resectable locally advanced rectal cancer (LARC): short-course RT (SC-RT) alone or long-course RT (LC-RT) with concurrent fluorouracil (5-FU) chemotherapy. The Phase II single-arm KROG 11-02 study using intermediate-course (IC) (33 Gy (Gray)/10 fr (fraction) with concurrent capecitabine) preoperative chemoradiotherapy (CRT) demonstrated a pathologically complete response rate and a sphincter-sparing rate that were close to those of LC-CRT. The current trial aim to compare the pathological/oncological outcomes, toxicity, and quality of life results of LC-CRT and IC-CRT in cases of… More >

  • Open Access

    ARTICLE

    Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study

    OZAN CEM GULER1,*, EZGI OYMAK2, GOZDE YAZICI3, OZLEM OZKAYA AKAGUNDUZ4, OGUZ CETINAYAK5, PETEK ERPOLAT6, ATIL AKSOY7, MURSEL DUZOVA8, BERNA AKKUS YILDIRIM9, MERAL KURT10, EMINE CANYILMAZ11, GULER YAVAS12, SERAP AKYUREK13, DIDEM COLPAN OKSUZ14, ESRA KAYTAN SAGLAM15, OMUR KARAKOYUN CELIK16, ENIS OZYAR17, MUSTAFA CENGIZ3, CEM ONAL1,2,12

    Oncology Research, Vol.31, No.3, pp. 299-306, 2023, DOI:10.32604/or.2023.028840

    Abstract The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni- and multivariable analyses. The median age of the entire cohort was 56 years (range: 26–87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and… More >

  • Open Access

    REVIEW

    Treatment options in stage I seminoma

    UROS BUMBASIREVIC1,2,*, MARKO ZIVKOVIC1, MILOS PETROVIC1, VESNA CORIC2,3, NIKOLA LISICIC1, NEBOJSA BOJANIC1,2

    Oncology Research, Vol.30, No.3, pp. 117-128, 2022, DOI:10.32604/or.2022.027511

    Abstract Seminomas are most commonly diagnosed in clinical stage I (CSI). After orchiectomy, approximately 15% of patients in this stage have subclinical metastases. Adjuvant radiotherapy (ART) delivered to the retroperitoneum and ipsilateral pelvic lymph nodes has been the mainstay of treatment for many years. Although highly efficient, with long-term cancer-specific survival (CSS) rates approaching almost 100%, ART is associated with considerable long-term consequences, particularly cardiovascular toxicity and increased risk of secondary malignancies (SMN). Therefore, active surveillance (AS) and adjuvant chemotherapy (ACT) were developed as alternative treatment options. While AS prevents patient overtreatment, it is associated with… More >

Displaying 1-10 on page 1 of 15. Per Page